Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.
about
The clinically relevant pharmacogenomic changes in acute myelogenous leukemiaCIViC databaseFavorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewCXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemiaClinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.Nucleophosmin suppresses oncogene-induced apoptosis and senescence and enhances oncogenic cooperation in cells with genomic instability.Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia?Performance and clinical evaluation of a sensitive multiplex assay for the rapid detection of common NPM1 mutationsMutated NPM1 in patients with acute myeloid leukemia in remission and relapse.Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samples.Clinical relevance of mutant NPM1 and CEBPA in patients with acute myeloid leukaemia - preliminary reportMRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosisA knock-in Npm1 mutation in mice results in myeloproliferation and implies a perturbation in hematopoietic microenvironmentHigh DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia.Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia.Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.Monoclonal antibodies against nucleophosmin mutants: potentials for the detection of acute myeloid leukemia.Clofarabine for the treatment of adult acute myeloid leukemia.FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.The incidence and clinical significance of nucleophosmin mutations in childhood AML.The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.Fusion tyrosine kinase mediated signalling pathways in the transformation of haematopoietic cells.Nucleophosmin: a versatile molecule associated with hematological malignancies.Detection of mutant NPM1 mRNA in acute myeloid leukemia using custom gene expression arrays.Detection of NPM1 exon 12 mutations and FLT3 - internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia.Acute myeloid leukaemia: optimal management and recent developments.Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.HOX expression patterns identify a common signature for favorable AML.Transcription factor C/EBPα-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemiaMolecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia.Role of nucleophosmin in acute myeloid leukemia.Pharmacogenomics in acute myeloid leukemia.Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients.
P2860
Q27014790-16E41851-ADE2-4AC1-8B47-435139AC69FAQ27612411-6612A145-B0FE-49A6-B00F-6F534DCC6A33Q27851545-94A5A061-C889-48F9-8533-98AECD6BBD92Q27853004-0DC8ADB6-EF03-4A83-9DD9-D27AEF12F4AEQ28301344-BE23F6D6-1A76-439D-8B46-15A1E48A5B8CQ33410331-147CE24F-8C8A-48CE-92F1-43E156F555C9Q33572303-DF2F6FA1-2764-4CD6-A797-ABD4514AC342Q33773430-2E44F587-4696-451F-90CA-E60EB7C54B9AQ33800539-F7917970-5F05-4022-849A-7A8DC08A49A5Q34084839-548CDA33-0CAB-427A-A899-78D7653D466AQ34086334-53D29BB8-240E-4A9F-A103-7CBCFB2AA304Q34144877-0058E0A7-6049-4890-BB76-7D0D8CD01EC6Q34226754-F0D73D59-877F-4875-B69B-9A75AFFF943EQ34227693-E931A9A6-7F8A-4C07-8395-C21D4268EFD6Q34349257-91068BDD-BB28-4C29-AEB1-BDA1EF140234Q34505038-B98EBB48-5022-4D24-9C97-92672B2264F9Q34516815-68BA0E6A-5059-455B-95C9-39E92BE435ABQ34627568-FCBD04A4-C4AE-4E26-B22B-0B3B4C812F3CQ34635511-A2BAEE57-785A-4895-9848-532FC0AF8CA6Q34755985-C95C66D4-ED64-4206-8409-5F5664F10A8EQ35001805-BB4EC76C-B7C4-44F3-A624-DD798E476554Q35009273-3138A72D-BE99-4343-A5C0-992DAC436522Q35048217-52E24A89-9F41-499A-9F34-8BA047251EE1Q35615901-A47E558F-E7CD-4415-9FF4-C6D56A353EC1Q35848938-12B60A7C-891A-4375-B64E-D47B322D0942Q35901721-125B9B02-CC6E-42D2-BF85-072D60E40E01Q36254225-F61F69BD-00E3-4380-912D-8F2D4F134AE5Q36398134-5073E9B7-9787-4278-B47F-C077B3CEDE8EQ36597677-04ED03F4-B605-4A10-8B41-5DD97E40B0EEQ36720677-1B1FD21A-6E04-450B-9044-8B7D5F281AA5Q36840125-19B2D02E-C90E-44D3-9262-D734AD9B8124Q36914091-D946C76F-6A90-4005-A423-5DB4479A46A5Q37119445-91D8BB60-126D-4240-B090-35EECDFDBA1FQ37176769-FF69E96B-5A2C-429B-8171-FA3AD30977FFQ37215151-DC6B4094-72BA-4BAB-BFD8-35AC9629D172Q37236994-E6023A74-5C96-4866-AAA5-FDD542F4F240Q37587536-E07AEB29-B2EC-44A3-B7A1-4BD8A834F8D9Q37598941-E4FFFDA1-A330-42D4-B521-D968227407F2Q37627876-D7B7DFF0-0FD9-4D6C-8FC0-A88FEBB34C5DQ37645063-3813E68B-B11E-4FE3-AC40-D533FF3839EC
P2860
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Prevalence, clinical profile, ...... in AML with normal karyotype.
@ast
Prevalence, clinical profile, ...... in AML with normal karyotype.
@en
Prevalence, clinical profile, ...... in AML with normal karyotype.
@nl
type
label
Prevalence, clinical profile, ...... in AML with normal karyotype.
@ast
Prevalence, clinical profile, ...... in AML with normal karyotype.
@en
Prevalence, clinical profile, ...... in AML with normal karyotype.
@nl
prefLabel
Prevalence, clinical profile, ...... in AML with normal karyotype.
@ast
Prevalence, clinical profile, ...... in AML with normal karyotype.
@en
Prevalence, clinical profile, ...... in AML with normal karyotype.
@nl
P2093
P50
P3181
P1433
P1476
Prevalence, clinical profile, ...... in AML with normal karyotype.
@en
P2093
Christine Terre
Emmanuel Raffoux
Isabelle Tigaud
Jean-Michel Cayuela
Nathalie Philippe
Nicolas Boissel
Sylvie Castaigne
Valeria Biggio
Xavier Thomas
P304
P3181
P356
10.1182/BLOOD-2005-05-2174
P407
P577
2005-11-15T00:00:00Z